neuroendocrine tumor Archives
Targeted therapy for neuroendocrine tumors
Feb. 16, 2023—Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.
Clinical score can guide PRRT therapy decisions for neuroendocrine tumors
Jan. 19, 2022—A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.
Shifts in neuroendocrine cancer clinical trial design
Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.
Das lands support for neuroendocrine tumor research
Mar. 5, 2020—Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.
Midgut neuroendocrine tumor prognosis
Jan. 6, 2017—Vanderbilt investigators recommend that the presence of tumor deposits in the abdomen be included when staging midgut neuroendocrine tumors.
Superior scan for tumors
Jun. 24, 2016—Imaging with a compound that binds to neuroendocrine cells is a safer and more effective way to detect rare neuroendocrine tumors.
Biomarker for intestinal tumors
Oct. 21, 2015—A new marker could be useful for diagnosing and treating neuroendocrine tumors of the small intestines.
VICC debuts novel neuroendocrine tumor treatment
Apr. 24, 2014—A retired elementary school principal has become the first patient at Vanderbilt-Ingram Cancer Center to receive an investigational cancer therapy for the treatment of his neuroendocrine tumor.
